All In Biotech

Drug Trial Radar · NCT07175233

A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis

A Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

184

Actual

Start

Oct 28, 2025

Primary completion

Sep 23, 2026

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled multicenter clinical study to evaluate the efficacy, safety, and pharmacokinetics of SIM0278 in adult patients (18-75 years) with moderate to severe AD suitable for systemic therapy. Approximately 184 subjects with moderate to severe AD are planned to be randomized in a 1: 1: 1: 1 ratio to SIM0278 low dose, SIM0278 medium dose, SIM0278 high dose, or placebo. Subjects were stratified at randomization by baseline disease severity (moderate \[IGA = 3\] VS severe \[IGA = 4\]). The study consisted of 4 phases: screening, double-blind induction, open-label maintenance, and safety follow-up.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • SIM0278 injectionDrug

    SIM0278 injection

  • PlaceboOther

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 16 (W16).Time frame: At Week 16 (W16)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University

    Hangzhou, China

  • The First Hospital of China Medical University

    Shenyang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.